Acquisition by Matthew Foehr of 10770 shares of OmniAb subject to Rule 16b-3

OABI Stock  USD 3.90  0.12  3.17%   
Under 63% of all OmniAb's traders are looking to take a long position. The analysis of the overall investor sentiment regarding OmniAb Inc suggests that some traders are interested. OmniAb's investing sentiment shows overall attitude of investors towards OmniAb Inc.
  
Filed transaction by OmniAb Inc Director, Officer: Chief Executive Officer. Grant, award or other acquisition pursuant to Rule 16b-3(d)

Read at finance.yahoo.com
Yahoo News
  
OmniAb insider trading alert for acquisition of common stock by Matthew Foehr, Director, Officer: Chief Executive Officer, on 18th of October 2024. This event was filed by OmniAb Inc with SEC on 2024-02-15. Statement of changes in beneficial ownership - SEC Form 4

OmniAb Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards OmniAb can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

OmniAb Fundamental Analysis

We analyze OmniAb's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of OmniAb using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of OmniAb based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

EBITDA

EBITDA Comparative Analysis

OmniAb is currently under evaluation in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

OmniAb Inc Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with OmniAb stock to make a market-neutral strategy. Peer analysis of OmniAb could also be used in its relative valuation, which is a method of valuing OmniAb by comparing valuation metrics with similar companies.

Peers

OmniAb Related Equities

IPSCCentury Therapeutics   20.74   
0%
100.0%
ACETAdicet Bio   15.63   
0%
75.0%
PASGPassage Bio   11.94   
0%
57.0%
GLUEMonte Rosa   5.93   
0%
28.0%
ERASErasca   5.04   
0%
24.0%
BCABBioatla   4.46   
0%
21.0%
ITOSIteos Therapeutics   4.27   
0%
20.0%
OLMAOlema Pharmaceuticals   4.12   
0%
19.0%
CGEMCullinan Oncology   2.51   
0%
12.0%
KROSKeros Therapeutics   2.02   
0%
9.0%
LEGNLegend Biotech   1.29   
0%
6.0%
IDYAIdeaya Biosciences   0.78   
0%
3.0%
PMVPPmv Pharmaceuticals   0.63   
0%
3.0%
VRNAVerona Pharma   0.15   
0%
1.0%
EWTXEdgewise Therapeutics   0.37   
1.0%
0%
IKNAIkena Oncology   1.17   
5.0%
0%
VORVor Biopharma   1.25   
6.0%
0%

Complementary Tools for OmniAb Stock analysis

When running OmniAb's price analysis, check to measure OmniAb's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OmniAb is operating at the current time. Most of OmniAb's value examination focuses on studying past and present price action to predict the probability of OmniAb's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OmniAb's price. Additionally, you may evaluate how the addition of OmniAb to your portfolios can decrease your overall portfolio volatility.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon